Specialists from the Nacimbio, the pharmaceutical holding company of Rostec State Corporation, have created a combination vaccine for the immunoprophylaxis of diphtheria, tetanus, and whooping cough in adults. This vaccine has successfully completed clinical trials, demonstrating high efficacy and safety. The documentation has been submitted to the Russian Ministry of Health for registration in accordance with EAEU regulations.
The uniqueness of this vaccine lies in its reduced concentrations of diphtheria and tetanus toxoids, along with the inclusion of an acellular whooping cough component, allowing it to be used for revaccination in individuals over 18 years of age. Large-scale clinical trials conducted at 10 scientific centers across Russia involved 436 volunteers from various age groups. The results indicated that most participants developed a protective antibody titer against the targeted infections, with excellent tolerability reported for the vaccine.
